Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event?
Minuz
Pietro
P
D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011464:Epoprostenol / Q000037:antagonists & inhibitors; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced*
D052246:Cyclooxygenase 2 Inhibitors; D011464:Epoprostenol